BenzingaDoubao · 实盘不做把握 7/10不做原因:已被定价
北京时间·🕒 发布 01:11:04·⟳ 抓取 01:11:09 +5s·⚡ 决策 10-21 02:07:46 +56m37s·6.8 天前
Actinium Pharmaceuticals（ATNM.US）公布 ATNM-400 首个人体 I 期 mCRPC 初步安全性数据，股价盘中一度涨近 9%
数据增量薄弱（最低剂量组 3 例、仅安全性、无疗效），而 EANM 口头报告早在 10/15 即由公司预告，股价 10/15-10/19 已连续大涨（+8.8%、+6.6%、+16.8%），今日借媒体报道盘中冲高后回落，预期已被大幅提前定价；不追多，亦无实质利空可供做空。
📄 原文Benzinga↗ 原文
Why Is Actinium Pharmaceuticals Stock Gaining Tuesday?
On Tuesday, Actinium Pharmaceuticals Inc. (NYSE:ATNM) announced encouraging initial clinical results from its first-in-…
不做 Actinium Pharmaceuticals, Inc.（ATNM.US）
已 price-in 且数据信息量不足：EANM 报告 10/15 已官方预告，股价三个交易日提前上涨约 35%；正式数据仅为 I 期最低剂量组 3 例患者的安全性结果、无任何疗效信号，Benzinga 盘中报道属二次扩散且价格冲高回落，追多无 edge；数据方向偏正面、不构成做空催化，故双向回避
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
ATNM-400 仅公布 I 期最低剂量 3 例患者的安全性结果，无疗效证据；报告日期 5 天前已明牌，股价 3 个交易日已涨约 35%，Benzinga 报道属二次扩散且盘中冲高回落，追高 edge 不足，回避。
消息传播链
- 公司 10 月 15 日公告将在 EANM 2026 口头报告 ATNM-400 首个人体 I 期前列腺癌研究，催化日期与内容提前明牌市场反应:当日（10/15）股价 +8.76%，次日 +6.6%
- EANM 现场正式披露初步数据：1.0 µCi/kg 组 3 例无 DLT，剂量推进至 1.5 µCi/kg，无疗效数据
- Benzinga 盘中报道股价涨近 9%、成交量为百日均量 4.4 倍；研判时（14:06 ET）涨幅回落至约 +6.8%，冲高回落市场反应:盘中一度 +8.85% 至 1.43 美元，随后回落至 1.41 美元附近（+6.8%）
关键理由
- 不做多：3 例最低剂量组无 DLT 在 I 期 3+3 设计中属低信息量结果，未提供任何 PSA/生存疗效信号
- 不追价：EANM 报告 10/15 已预告，近三日股价 +35%、量能放大，今日 +9% 后回落至 +7%，明牌事件兑现特征明显
主要风险
- 若高剂量组出现疗效信号或后续公布超预期 PSA 缓解，微盘股（市值约 4400 万美元）可能继续逼空式上涨
- 微盘临床期生物科技股波动极大、成交稀疏（20 日日均成交额约 16 万美元），买卖价差大且融资摊薄风险长期存在
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-20 · 影响 weakens
官方新闻稿与报道均无 PSA 缓解、rPFS、OS 等任何疗效信号，仅 3 例最低剂量安全性；I 期 3+3 设计中最低剂量无 DLT 信息量低
检索:Actinium ATNM-400 phase 1 efficacy PSA response dose limiting toxicity October 2026 原文 ↗ - 做多前查反向 · 来源 futu · 日期 2026-10-19 · 影响 invalidates
行情显示 10/15 +8.76%、10/16 +6.6%、10/19 +16.81%，事件前三个交易日已累计上涨约 35%，10/20 盘中冲高回落，量比 5.83，明牌抢跑充分
检索:ATNM stock October 15 16 19 2026 rally EANM pre-run
先例如何影响了这次决策
对本次决策的影响:先例不足与弱数据、强抢跑共同支持回避，不支持追多
方向:未构建先例面板：本轮事件为极低市值临床期公司 I 期最低剂量组安全性读出，可比对齐样本（同公司、同会议、同阶段首日人体数据）需系统检索，且本案核心否决依据是明牌提前定价与数据信息量不足，不依赖先例幅度
涨幅量级:无高相似对齐先例校准幅度，不用类比数字设定止盈止损
形态:个股自身轨迹已显示典型的'预告日启动、事件日媒体扩散冲高回落'形态（10/15、10/16、10/19 连涨后 10/20 盘中回落）
工具执行结果 · 成功 5 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 13 ms
{"result": "search_processed_events:agent query=`actinium pharmaceuticals atnm-400 phase 1 mcrpc eanm | atnm-400 her3 alpha radiotherapy actinium-225 barecetamab first-in-human results`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判 - fetch_decision_experience 成功 stock_tools_inprocess · 3 ms
{ - stock_quote 成功 stock_tools HTTP · 210 ms
{ - web_search 成功 doubao_search · 1,069 ms
豆包搜索结果（原始查询:Actinium Pharmaceuticals ATNM-400 EANM 2026 Phase 1 prostate cancer presentation abstract date；API SearchType:web） - web_search 成功 doubao_search · 1,412 ms
豆包搜索结果（原始查询:Actinium Pharmaceuticals ATNM stock October 19 2026 news offering cash；API SearchType:web）
原文全文
展开原文 · 2,878 字
On Tuesday, Actinium Pharmaceuticals Inc. (NYSE:ATNM) announced encouraging initial clinical results from its first-in-human Phase 1 study of ATNM-400 for metastatic castration-resistant prostate cancer (mCRPC).
The company presented its findings at the Annual Congress of the European Association of Nuclear Medicine, demonstrating a favorable early safety profile and sustained tumor retention.
Following the announcement, the stock jumped nearly 9%. Trading volume reached 670,435 shares, more than 4.4 times the 100-day average of 150,386 shares, signaling unusually heavy trading activity.
Initial Safety Profile And Dose Escalation
The ongoing first-in-human trial employs a 3+3 dose-escalation framework in patients with progressive mCRPC who previously received at least one androgen receptor pathway inhibitor and at least one taxane regimen.
Investigators cleared the initial dose level of 1.0 µCi/kg across three heavily pretreated patients, all of whom received at least two cycles of ATNM-400, including two patients who completed three cycles. One patient had also previously undergone ¹⁷⁷Lu-PSMA therapy.
During the dose-limiting toxicity evaluation window and subsequent monitoring, researchers identified no dose-limiting toxicities, xerostomia, or Grade 3 or 4 hematologic adverse events.
Clinicians also observed no elevations in liver enzymes or creatinine, and no infusion-related or injection-site reactions.
Following the clearance of the initial cohort, dose escalation advanced to 1.5 µCi/kg, with additional planned increments at 2.25 and 3.0 µCi/kg.
Targeted Radiotherapy Mechanism And Theranostics
ATNM-400 represents a first-in-class, HER3-directed alpha radiotherapy that conjugates the monoclonal antibody barecetamab with Actinium-225 (²²⁵Ac).
Because HER3 promotes disease progression and resistance to androgen receptor pathway inhibitors, the agent offers a biology-driven treatment mechanism beyond PSMA.
Preclinical tests showed robust antitumor activity across PSMA-high, PSMA-low, and PSMA-negative models, as well as models exhibiting low HER3 expression.
The clinical trial uses a theranostic approach, conducting HER3-targeted PET scans using Zirconium-89-labeled barecetamab prior to intravenous ATNM-400 infusions given every six weeks.
Serial imaging verified that tumors retained the agent through Day 7, closely aligning with the 10-day half-life of ²²⁵Ac.
The study aims to determine the recommended Phase 2 dose while evaluating PSA responses, overall survival, and radiographic progression-free survival.
ATNM Price Action: Actinium Pharmaceuticals shares were up 8.85% at $1.43 at the time of publication on Tuesday, according to Benzinga Pro data.
Image via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
The company presented its findings at the Annual Congress of the European Association of Nuclear Medicine, demonstrating a favorable early safety profile and sustained tumor retention.
Following the announcement, the stock jumped nearly 9%. Trading volume reached 670,435 shares, more than 4.4 times the 100-day average of 150,386 shares, signaling unusually heavy trading activity.
Initial Safety Profile And Dose Escalation
The ongoing first-in-human trial employs a 3+3 dose-escalation framework in patients with progressive mCRPC who previously received at least one androgen receptor pathway inhibitor and at least one taxane regimen.
Investigators cleared the initial dose level of 1.0 µCi/kg across three heavily pretreated patients, all of whom received at least two cycles of ATNM-400, including two patients who completed three cycles. One patient had also previously undergone ¹⁷⁷Lu-PSMA therapy.
During the dose-limiting toxicity evaluation window and subsequent monitoring, researchers identified no dose-limiting toxicities, xerostomia, or Grade 3 or 4 hematologic adverse events.
Clinicians also observed no elevations in liver enzymes or creatinine, and no infusion-related or injection-site reactions.
Following the clearance of the initial cohort, dose escalation advanced to 1.5 µCi/kg, with additional planned increments at 2.25 and 3.0 µCi/kg.
Targeted Radiotherapy Mechanism And Theranostics
ATNM-400 represents a first-in-class, HER3-directed alpha radiotherapy that conjugates the monoclonal antibody barecetamab with Actinium-225 (²²⁵Ac).
Because HER3 promotes disease progression and resistance to androgen receptor pathway inhibitors, the agent offers a biology-driven treatment mechanism beyond PSMA.
Preclinical tests showed robust antitumor activity across PSMA-high, PSMA-low, and PSMA-negative models, as well as models exhibiting low HER3 expression.
The clinical trial uses a theranostic approach, conducting HER3-targeted PET scans using Zirconium-89-labeled barecetamab prior to intravenous ATNM-400 infusions given every six weeks.
Serial imaging verified that tumors retained the agent through Day 7, closely aligning with the 10-day half-life of ²²⁵Ac.
The study aims to determine the recommended Phase 2 dose while evaluating PSA responses, overall survival, and radiographic progression-free survival.
ATNM Price Action: Actinium Pharmaceuticals shares were up 8.85% at $1.43 at the time of publication on Tuesday, according to Benzinga Pro data.
Image via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
581146273f· 2026-10-21 02:07 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前